Clinical trials: Psoriatic Arthritis
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Behçet's Disease, Juvenile Psoriatic Arthritis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic…
- Trial name
- NCT05767047
- Testing
- Apremilast
- Where
- 7 sites in Greece, Israel and 2 more
- Volunteers
- 48 people
- Sponsor
- Amgen
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites.
- Trial name
- NCT06666114
- Where
- Brazil
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.
- Trial name
- NCT02772601
- Testing
- Caffeine, Warfarin, Omeprazole
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Joint Diseases, Osteoarthritis, Hip
Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System
The objective of this study is to evaluate patient outcomes in regards to safety and effectiveness based on the clinical performance of the reference devices to further support the assessment of residual risk identified in the…
- Conditions
- Joint Diseases, Osteoarthritis, Hip, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- NCT03986918
- Testing
- Routine Total Hip Arthroplasty
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Ortho Development Corporation
Psoriatic Arthritis
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
- Trial name
- NCT00245960
- Testing
- etanercept
- Where
- 120 sites in Argentina, Australia and 24 more
- Volunteers
- 752 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis
In Spain, there is little data available concerning the evolution and treatment of Psoriatic Arthritis by rheumatologists and dermatologists.
- Trial name
- NCT00580632
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis, Psoriatic Arthritis
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
- Trial name
- NCT00643526
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Centocor, Inc.
PsA (Psoriatic Arthritis)
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
- Trial name
- D2570-204 (NCT07315061)
- Testing
- D-2570
- Where
- China
- Volunteers
- 222 people
- Sponsor
- InventisBio Co., Ltd
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
- Trial name
- NCT03963401
- Testing
- PF-06700841
- Where
- 48 sites in Australia, Bulgaria and 9 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese male subjects A total of 182 subjects are planned…
- Trial name
- NCT04152759
- Testing
- Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Psoriatic Arthritis
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to…
- Trial name
- FUTURE5 (NCT02404350)
- Testing
- Secukinumab
- Where
- 172 sites in United States, Argentina and 26 more
- Volunteers
- 997 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red…
- Trial name
- GURU (NCT07220824)
- Where
- 21 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an…
- Trial name
- OPAL BROADEN (NCT01877668)
- Testing
- Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab
- Where
- 123 sites in United States, Australia and 14 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Psoriatic Arthritis
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis.
- Trial name
- PERIS (NCT06764693)
- Where
- 132 sites in Argentina, Austria and 13 more
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the…
- Trial name
- COSMOS (NCT03796858)
- Testing
- Guselkumab 100 mg
- Where
- 117 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 285 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium